Valius Sciences

The founding team brings together expertise from diverse and relevant fields. CEO Edward Larkin previously built the healthcare business at Palantir Technologies and managed life sciences investments at Dragoneer Investment Group. COO Claire Oldfield was an Associate Partner in the healthcare and life sciences practice at Bain & Company, and holds a PhD in neuroscience. Head of Translational Science Sarah Hesse has a background in immuno-oncology and computational biology from her time at Takeda and Intellia Therapeutics, with a PhD in bioengineering from MIT.

The company's approach involves extensive testing to identify actionable targets and cancer drivers, utilizing gene expression (RNA) data to find targets often missed by standard genetic tests. This 'maximalist' diagnostic approach analyzes a patient's tumor behavior against thousands of other samples to evaluate targets and treatment options intelligently. Unlike traditional diagnostics companies that provide static PDF reports, Valius offers a partnership model, giving patients and their care teams ongoing access to all their data through an accessible, shareable, and AI-queryable platform. This allows for continuous analysis, contextualization, and collaboration with Valius's scientific team. The company partners with patients at various stages, from those in remission who want to prepare for potential recurrence to those with active disease who have exhausted standard care options.